Cardiac expression of neutrophil gelatinase‐associated lipocalin in a model of cancer cachexia‐induced cardiomyopathy

Abstract

AimsCachexia is a severe consequence of cancer. Although cancer‐induced heart atrophy leads to cardiac dysfunction and heart failure (HF), biomarkers for their diagnosis have not been identified. Neutrophil gelatinase‐associated lipocalin (NGAL) is an aldosterone‐responsive gene increased in HF. We studied NGAL and its association with aldosterone levels in a model of cancer cachexia‐induced cardiomyopathy.Methods and resultsRats were injected with Yoshida 108 AH‐130 hepatoma cells to induce tumour. Cachectic rats were treated daily, for 16 days, with placebo or with 5 or 50 mg/kg/day of spironolactone. Cardiac function was analysed by echocardiography at baseline and at Day 11. Weight loss and atrophy of lean body and fat mass of cachectic rats were significantly attenuated by spironolactone. Cardiac dysfunction of tumour‐bearing rats was improved by spironolactone. Plasma aldosterone was up‐regulated from 337 ± 7 pg/mL in sham animals to 591 ± 31 pg/mL in the cachectic rats (P < 0.001 vs. sham). Treatment with 50 or 5 mg/kg/day of spironolactone reduced plasma aldosterone to 396 ± 22 and 391 ± 25 pg/mL (P < 0.01 vs. placebo). Plasma levels of NGAL were also increased in cachectic rats (1.462 ± 0.3603 μg/mL) than in controls (0.0936 ± 6 μg/mL, P < 0.001). Spironolactone treatment (50 mg/kg/day) significantly reduced cardiac mRNA and protein NGAL levels (P < 0.05 and P < 0.001 vs. placebo, respectively). NGAL mRNA and protein levels were overexpressed in cachectic animal hearts treated with placebo, compared with control (P < 0.05 and P < 0.01 vs. sham). Spironolactone treatment at 50 mg/kg/day reduced significantly cardiac NGAL (P < 0.05 and P < 0.001 vs. placebo).ConclusionsCancer cachexia induced increased levels of aldosterone and NGAL, contributing to worsening cardiac damage in cancer cachexia‐induced cardiomyopathy. Spironolactone treatment may greatly attenuate cardiac dysfunction and lean mass atrophy associated with cancer cachexia.

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease

“…Protein extraction and SDS-PAGE Western Blot analysis. Tissue lysates were prepared as previously described 38,39 . Briefly, 200 mg of liver were homogenized in 300 μL ice-cold lysis buffer (100 mM Tris pH 7,6; 300 mM KCl; 0,1% Triton X 100; 10 μL/mL freshly added protease and phosphatase inhibitor cocktails), centrifuged at 20.000 g for 20 min at 4 °C and supernatant was collected.…”

Cachexia as a common characteristic in multiple chronic disease

“…Several other studies investigated patients with different types of gastrointestinal cancer and reported either a loss of muscle tissue or a loss of both skeletal muscle and adipose tissue mass . In addition, loss of cardiac muscle tissue in cancer cachexia (CC) has been shown in clinical and experimental studies …”

Dysregulation of phosphoproteins in hepatocellular carcinoma revealed via quantitative analysis of the phosphoproteome

“…Additionally, KEGG enrichment analysis of the phosphorylated proteins revealed pathways associated with arrhythmogenic right ventricular cardiomyopathy. This may be explained by the elevated levels of aldosterone and neutrophil gelatinase-associated lipocalin that are induced by cancer cachexia ( 56 ).…”